BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17361988)

  • 1. Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49.
    Tang Y; Yang S; Gariépy J; Scollard DA; Reilly RM
    Bioconjug Chem; 2007; 18(3):677-84. PubMed ID: 17361988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
    Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
    J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
    Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
    Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.
    Zou P; Xu S; Povoski SP; Wang A; Johnson MA; Martin EW; Subramaniam V; Xu R; Sun D
    Mol Pharm; 2009; 6(2):428-40. PubMed ID: 19718796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
    Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
    Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
    Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
    World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
    Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
    Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
    Chinn PC; Morena RA; Santoro DA; Kazules T; Kashmiri SV; Schlom J; Hanna N; Braslawsky G
    Cancer Biother Radiopharm; 2006 Apr; 21(2):106-16. PubMed ID: 16706631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
    Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
    Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
    Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
    Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
    Schott ME; Frazier KA; Pollock DK; Verbanac KM
    Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
    Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
    Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Schlom J
    Cancer Res; 1992 Jun; 52(12):3402-8. PubMed ID: 1596900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.